title: Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation.
abstract: OBJECTIVE
  The aim of this study was to evaluate whether addition of omega-3 fatty acids or increase in aspirin dose improves response to low-dose aspirin among patients who are aspirin resistant.
  
  
  BACKGROUND
  Low response to aspirin has been associated with adverse cardiovascular events. However, there is no established therapeutic approach to overcome aspirin resistance. Omega-3 fatty acids decrease the availability of platelet arachidonic acid (AA) and indirectly thromboxane A2 formation.
  
  
  METHODS
  Patients (n = 485) with stable coronary artery disease taking low-dose aspirin (75 to 162 mg) for at least 1 week were screened for aspirin response with the VerifyNow Aspirin assay (Accumetrics, San Diego, California). Further testing was performed by platelet aggregation. Aspirin resistance was defined by > or =2 of 3 criteria: VerifyNow score > or =550, 0.5-mg/ml AA-induced aggregation > or =20%, and 10-micromol/l adenosine diphosphate (ADP)-induced aggregation > or =70%. Thirty patients (6.2%) were found to be aspirin resistant and randomized to receive either low-dose aspirin + omega-3 fatty acids (4 capsules daily) or aspirin 325 mg daily. After 30 days of treatment patients were re-tested.
  
  
  RESULTS
  Both groups (n = 15 each) had similar clinical characteristics. After treatment significant reductions in AA- and ADP-induced aggregation and the VerifyNow score were observed in both groups. Plasma levels of thromboxane B2 were also reduced in both groups (56.8% reduction in the omega-3 fatty acids group, and 39.6% decrease in the aspirin group). Twelve patients (80%) who received omega-3 fatty acids and 11 patients (73%) who received aspirin 325 mg were no longer aspirin resistant after treatment.
  
  
  CONCLUSIONS
  Treatment of aspirin-resistant patients by adding omega-3 fatty acids or increasing the aspirin dose seems to improve response to aspirin and effectively reduces platelet reactivity.
authors.affiliation: Cardiology Department, Rabin Medical Center, Petah Tikva, Israel. elil@clalit.org.il
authors.forename: Eli I
authors.initials: EI
authors.lastname: Lev
authors.forename: Alejandro
authors.initials: A
authors.lastname: Solodky
authors.forename: Naama
authors.initials: N
authors.lastname: Harel
authors.forename: Aviv
authors.initials: A
authors.lastname: Mager
authors.forename: David
authors.initials: D
authors.lastname: Brosh
authors.forename: Abid
authors.initials: A
authors.lastname: Assali
authors.forename: Milton
authors.initials: M
authors.lastname: Roller
authors.forename: Alexander
authors.initials: A
authors.lastname: Battler
authors.forename: Neal S
authors.initials: NS
authors.lastname: Kleiman
authors.forename: Ran
authors.initials: R
authors.lastname: Kornowski
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage*; D003324:Coronary Artery Disease / Q000097:blood / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance / Q000187:drug effects*; D004359:Drug Therapy, Combination; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D015525:Fatty Acids, Omega-3; D005343:Fibrinolytic Agents; D001241:Aspirin